Associate Director, Therapeutic Development
McKesson Corporation | |
United States, Tennessee | |
Jun 27, 2026 | |
|
It's More Than a Career, It's a Mission. Our people are the foundation of our success. By joining our growing team at Sarah Cannon Research Institute (SCRI), a subsidiary of McKesson, you will have the opportunity to become part of one of the largest community-based cancer programs to advance oncology treatments and improve outcomes for cancer patients across the globe. We look for mission-driven candidates who have a desire to advance the fight against cancer and make a difference in the lives of patients diagnosed with cancer every day. Our Mission People who live with cancer - those who work to prevent it, fight it, and survive it - are at the heart of every decision we make. Bringing the most innovative medical minds together with the most passionate caregivers in their communities, we are transforming care and personalizing treatment. Through clinical excellence and cutting-edge research, SCRI is redefining cancer care around the world. Provide scientific leadership and operational oversight for early-phase Therapeutic Development programs. This role manages Clinical Program Scientists and is responsible for driving program execution, ensuring scientific rigor, and supporting the development and advancement of research strategies aligned to SCRI research priorities. This position operates as a working manager, balancing people leadership, scientific direction, and program execution in support of early-phase clinical research. Duties include but are not limited to: Program & Scientific Leadership
Team Leadership
Program Execution & Oversight
Cross-Functional Collaboration
Strategic & Operational Contributions
Mandatory: The following are mandatory expectations of all SCRI employees.
Minimum Qualifications:
This is a remote position based in the United States. Preference will be given to candidates located in the Nashville, TN area or those able to commute to our Nashville home office one day per week. Relocation and visa sponsorship are not available. Interested candidates should submit their application through https://www.scri.com/careers/. Applications will be accepted through July 6th, 2026. Please ensure all required materials are included as outlined in the posting. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S. Please click here to learn more about our research offerings. McKesson has become aware of online recruiting-related scams in which individuals who are not affiliated with or authorized by McKesson are using McKesson's (or affiliated entities, like CoverMyMeds or RxCrossroads) name in fraudulent emails, job postings or social media messages. In light of these scams, please bear the following in mind: McKesson Talent Advisors do not communicate with candidates via online chatrooms or using email accounts such as Gmail or Hotmail. Note that McKesson does rely on a virtual assistant (Gia) for certain recruiting-related communications with candidates. McKesson job postings are posted on our career site: careers.mckesson.com. We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. | |
Jun 27, 2026